Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from PCI Biotech Holding ASA ( (DE:4QG) ).
PCI Biotech announced its preliminary full-year 2024 results, highlighting significant progress in the scalability and manufacturing process of its photochemical-based technology (PCL) in viral vector manufacturing. The company achieved encouraging results with mini benchtop bioreactors, indicating potential for increased viral vector yield and reduced impurities. These advancements are expected to enhance net manufacturing yield, a crucial factor for the industry. PCI Biotech is preparing further test runs to validate these results and explore commercial opportunities, with plans for late-stage field testing in 2025. The company is also considering strategic opportunities to support operations as it aims to address capacity challenges in the commercial viral vector manufacturing market.
More about PCI Biotech Holding ASA
PCI Biotech is a biopharmaceutical company that focuses on developing and commercializing new technologies and novel therapies using its photochemical technology platform. Originating from research at Oslo University Hospital, the company is developing two main areas: photochemical lysis (PCL) for enhancing yield and purity in viral vector manufacturing, and photochemical internalization (PCI) for enabling light-triggered endosomal release.
YTD Price Performance: 31.00%
Average Trading Volume: 915
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €4.99M
For detailed information about 4QG stock, go to TipRanks’ Stock Analysis page.